Alcon, Allergan argue FDA pre-emption in defense against class-action suits.
This article was originally published in The Tan Sheet
Executive Summary
ALCON, ALLERGAN PRE-EMPTION DEFENSE IN CONTACT LENS SOLUTION LAWSUITS will be argued in hearings set for June 7 in the case of Nicholas v. Alcon and June 14 in Bruno v. Allergan. The two manufacturers will assert at the hearings in California Superior Court in San Diego that federal device law pre-empts the plaintiffs' claims of false advertising and unfair business practices.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning